兴奋剂
白细胞介素2
T细胞
受体
免疫
癌症治疗
癌症研究
白细胞介素
免疫学
神经科学
生物
作者
Aladdin M. Bhuiyan,Michael Dougan
标识
DOI:10.1016/j.tips.2021.11.003
摘要
Cancer therapy with the T cell growth factor interleukin (IL)-2 is limited by low response rates and toxicity. Multiple protein engineering strategies have attempted to improve IL-2 therapy, typically through enhanced IL-2 receptor (IL-2R) binding. Intriguingly, Mo et al. show that an IL-2R partial agonist may dramatically improve IL-2 responses by altering T cell differentiation.
科研通智能强力驱动
Strongly Powered by AbleSci AI